Sanofi released a statement Monday saying that the pharmaceutical company succeeded in its first late-stage trial of a new dengue vaccine. In the trial, the new vaccine reduced the occurrence of dengue fever by 56 percent in 10,275 children. This is a promising result, since 2.5 billion people are at risk for dengue worldwide, according to the World Health Organization.